Non-Radiographic Axial Spondyloarthritis Therapeutic Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Non-Radiographic Axial Spondyloarthritis Therapeutic Market Growth in 2025?
The therapeutic market for non-radiographic axial spondyloarthritis has seen significant expansion in recent times. Its growth is projected to increase from a worth of $0.93 billion in 2024, to $1.04 billion in 2025, displaying a compound annual growth rate (CAGR) of 10.9%. The surge in growth observed in the historic period can be attributed to a rise in the incidence of axial spondyloarthritis, better awareness and an enlarged patient pool, enhanced understanding of the disease spurring market growth, increasing research and development operations, and a surge in embraced biologic therapies.
What Is the Forecast for the Non-Radiographic Axial Spondyloarthritis Therapeutic Market Size Through 2029?
The market size for therapeutic solutions in non-radiographic axial spondyloarthritis is set to experience a quick surge in the coming years. It is projected to soar up to $1.55 billion by 2029 with a compound annual growth rate (CAGR) standing at 10.7%. The jump in growth during the projected phase is ascribed to the escalation in awareness and preliminary diagnosis, proliferation of biosimilars, continuous progression in biologics and emerging therapeutic alternatives in the pipeline. Additionally, the perpetual increase in research and development activities, the burgeoning use of targeted and personalized therapies and the enhancement in healthcare infrastructure also contribute to the growth. The forecast period will witness a prevalence of trends like personalized treatment plans, the incorporation of digital tools in diagnosis and a move toward treat-to-target (T2T) strategies. Furthermore, value-oriented pricing models and the acceptance of multidisciplinary management are also expected to take center stage.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24627&type=smp
What are the Key Market Players in Non-Radiographic Axial Spondyloarthritis Therapeutic Market and How They’re Evolving?
Major companies operating in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc., Johnson & Johnson, Allergan plc, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Mochida Pharmaceutical Co. Ltd., Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co. Ltd., Qyuns Therapeutics Co. Ltd.
What Are the Primary Growth Drivers in the Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
The surge in clinical trials is predicted to stimulate the expansion of the non-radiographic axial spondyloarthritis therapeutic market. These trials are studies carried out on humans to gauge the safety, efficacy, and possible side effects of new medical treatments or interventions. The escalation in clinical trials stems from the escalating need for innovative, tailored treatments that necessitate extensive safety and efficacy checks. These trials bolster non-radiographic axial spondyloarthritis therapeutics by yielding proof-driven validation of the effectiveness and safety in early-stage disease, which in turn influences regulatory sanctions and clinical acceptance. For instance, the Association of the British Pharmaceutical Industry, a UK-based trade body, reported in November 2023 that there had been a 15% spike in the annual enlistment to industry clinical trials in the UK, soaring from 36,722 participants in 2021-22 to 42,088 in 2022-23. Hence, the surge in clinical trials is boosting the growth of the non-radiographic axial spondyloarthritis therapeutic market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24627&type=smp
What Are the Leading Segments in the Global Non-Radiographic Axial Spondyloarthritis Therapeutic Industry?
The non-radiographic axial spondyloarthritis therapeutic market covered in this report is segmented –
1) By Type: Non-Steroidal Anti-Inflammatory Drugs, Biologics, Small Molecule Therapies, Corticosteroids
2) By Application: Oral, Injectable, Topical
3) By End User: Hospitals, Ambulatory Surgical Centers, Homecare Settings
Subsegments:
1) By Non-Steroidal Anti-Inflammatory Drugs: COX-2 Inhibitors, Non-Selective NSAIDs
2) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-17 (IL-17) Inhibitors
3) By Small Molecule Therapies: Janus Kinase (JAK) Inhibitors, Phosphodiesterase-4 (PDE4) Inhibitors
4) By Corticosteroids: Oral Corticosteroids, Intra-Articular Corticosteroid Injections
What Are the Key Market Trends in the Non-Radiographic Axial Spondyloarthritis Therapeutic Industry?
Key players in the non-radiographic axial spondyloarthritis (nr-axSpA) treatment market are prioritizing gaining regulatory permissions. These permissions are critical as it helps enhances business expansion, hasten the launch of innovative treatments, and achieve a competitive edge. These authorizations are comprised of official permissions from government bodies, which allows the legal marketing and prescription of a drug after its safety, effectiveness, and standard compliance have been demonstrated. Consider the case of AbbVie Inc., a US biopharmaceutical enterprise, which got an FDA green light in October 2022 for Rinvoq (upadacitinib). The approval is for treating adult patients with active nr-axSpA demonstrating inflammation indications and those who have not adequately reacted to TNF inhibitors. This approval signifies the sixth US sanction for Rinvoq and positions it as the first of its kind oral JAK inhibitor approved for nr-axSpA. This approval was based on the SELECT-AXIS 2 clinical trial findings, where nearly fifty percent of Rinvoq receivers registered substantial disease activity reduction compared to placebo within 14 weeks. Thus, it presents a novel once-a-day oral treatment choice for patients grappling with this intricate condition.
Access The Full Report Here:
What Is the Regional Outlook for the Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
North America was the largest region in the non-radiographic axial spondyloarthritis therapeutics market in 2024. The regions covered in the non-radiographic axial spondyloarthritis therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24627
This Report Delivers Insight On:
1. How big is the non-radiographic axial spondyloarthritis therapeutic market, and how is it changing globally?
2. Who are the major companies in the non-radiographic axial spondyloarthritis therapeutic market, and how are they performing?
3. What are the key opportunities and risks in the non-radiographic axial spondyloarthritis therapeutic market right now?
4. Which products or customer segments are growing the most in the non-radiographic axial spondyloarthritis therapeutic market?
5. What factors are helping or slowing down the growth of the non-radiographic axial spondyloarthritis therapeutic market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
